MEDIA RELEASE DOCTOR CALLS ON MINISTER LITTLE TO RELEASE ‘BURIED’ INDEPENDENT REPORT ON PHARMAC The final report of the Independent Pharmac Review...
Myeloma NZ
Dr Ken Romeril, of Wellington, receives his MNZM for services to haematology.
Congratulations on your very well-deserved appointment to The New Zealand Order of Merit for your services to Haematology! Dr Ken Romeril is a...
Updates on the Rapidly Changing Therapeutic Landscape in Multiple Myeloma
As we continue to understand more about the biology of multiple myeloma (MM) and the number of treatment options for patients with MM continues to...
Multiple Myeloma Media Release
The Cancer Control Agency’s analysis of the gap between Australia and New Zealand in funding 18 selected medicines with substantial clinical benefit...
Decision on access criteria for oral COVID-19 treatments
The Access Criteria for the oral antiviral COVID-19 treatments, nirmatrelvir with ritonavir (Paxlovid) and molnupiravir (Lagevrio) has been...
FRAIL-M TRIALS FOR TRANSPLANT INELIGIBLE MYELOMA (PHASE I/II)
Frail-M test
Honoured haematologist and HIV pioneer fears he won’t see action from ‘glacial’ Pharmac in his lifetime.
After New Year's Honours for his work, he now fears could die without seeing a single new myeloma-fighting drug added to those funded by Pharmac,...
COVID-19 information for patients and whānau with cancer.
This link here: Te Aho o Te Kahu - Cancer during COVID-19 contains information for patients and whānau with cancer. Cancer treatment continues at...
Pharmac Review Final Report – Update
In a radio interview today, Health Minister Andrew Little said the final Pharmac Review report will be publicised "in a matter of a few...
Newsletter: Autumn 2022
Dear All, I am writing this today and hearing about the 20,000 plus daily Covid-19 cases being reported which we know is probably half of the real...
Endorsers of the ICBCC Patient Impact Statement
Last Thursday 24 February the ICBCC Policy Strategy Working Group met to discuss on the Policy Strategy to address the specific impact of the...
Myeloma Australia’s Medical and Scientific Advisory Group (MSAG), article of the week
The primary analysis of the ICARIA-MM study showed significant improvement in progression-free survival with addition of isatuximab to...